Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reveiling is an injectable composite dermal filler developed by Aowita Biotech, combining hyaluronic acid (HA) and calcium hydroxyapatite (CaHA) microspheres. This formulation is specifically designed for facial contour sculpting and deep tissue structural support. The hyaluronic acid component provides immediate volumization and hydration of the extracellular matrix, while the calcium hydroxyapatite microspheres serve as a biostimulatory scaffold that promotes the infiltration of fibroblasts and the subsequent deposition of endogenous collagen. This dual-action mechanism results in both immediate aesthetic correction and long-term tissue remodeling. It is typically administered via deep dermal or sub-dermal injection to enhance facial contours and provide structural support.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Reveiling.